AB-3028

· Arsenal Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AB-3028, covering 2026-03-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]

See pricing